| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-12-03 | Bio-Modeling Systems (France) Aepodia (Belgium) | fibromyalgia, chronic facial pain | R&D |
R&D agreement | ||
| 2013-12-03 | Selexis (Switzerland) JHL Biotech (Taiwan) | cGMP manufacturing services | collaboration |
Technology - Services | Collaboration agreement | |
| 2013-12-02 | MDX Health (Belgium) HealthSmart (USA) | ConfirmMDx for Prostate Cancer | prostate cancer | Cancer - Oncology | Distribution agreement | |
| 2013-12-02 | MDxHealth (Belgium) Fortified Provider Network (USA) | ConfirmMDx for Prostate Cancer | prostate cancer | Cancer - Oncology | Distribution agreement | |
| 2013-12-02 | ProJect Pharmaceutics (Germany) ImevaX (Germany) | IMX101 (recombinant vaccine against Helicobacter pylori) | Helicobacter pylori infection | development |
Infectious diseases | Development agreement |
| 2013-12-02 | Novartis (Switzerland) Unilife (USA) | Technology - Services | Services contract | |||
| 2013-11-28 | Biocartis (Belgium) bioMerieux (France) | platform Idylla™ | development |
Diagnostic | Termination of an agreement | |
| 2013-11-26 | Merrimack Pharmaceuticals (USA) Actavis (Ireland) | nanoliposomal technology platform | collaboration |
Technology - Services | Collaboration agreement | |
| 2013-11-25 | Summit (UK) Oxford University (UK) | early-stage utrophin modulators | Duchenne Muscular Dystrophy | R&D |
Genetic diseases - Neuromuscular diseases - Rare diseases | R&D agreement |
| 2013-11-22 | MolMed (Italy) GSK (UK) | gene therapy | ADA-SCID (Adenosine Deaminase Deficiency – Severe Combined Immune Deficiency) | manufacturing |
Rare diseases - Genetic diseases | Production agreement |
| 2013-11-22 | Galapagos (Belgium) Gilead Sciences (USA - CA) | GLPG0634 (filgotinib) | Crohn's disease, rheumatoid arthritis | development commercialisation | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Digestive diseases | Milestone |
| 2013-11-21 | Covagen (Switzerland) Mitsubishi Tanabe Pharma (Japan) | Fynomer-antibody platform | R&D |
Technology - Services | R&D agreement | |
| 2013-11-20 | GSK (UK) Amicus Therapeutics (USA - NJ) | migalastat HCl | Fabry disease | licensing |
Rare diseases - Genetic diseases | Licensing agreement |
| 2013-11-20 | Biopharm (Germany) Merck KGaA, Merck Serono (Germany) | pro-anabolic osteoarthritis modifying drug based on a growth factor derived from the Biopharm growth factor platform technology | osteoarthritis | R&D |
Rheumatic diseases - Inflammatory diseases | R&D agreement |
| 2013-11-20 | Biofocus, a Galapagos Company (UK - Belgium) Boehringer Ingelheim (Germany) | discovery services | undisclosed | R&D |
undisclosed | R&D agreement |
| 2013-11-20 | Vect-Horus (France) Advanced Accelerator Applications (AAA) (France) | R&D |
CNS diseases | R&D agreement | ||
| 2013-11-19 | Curie-Cancer (France) Meiogenix (France) INRA (France) | SpiX technology | licensing |
Licensing agreement | ||
| 2013-11-19 | Roche (Switzerland) Viriom (Russia) | VM-1500 | HIV | development |
Infectious diseases | Development agreement |
| 2013-11-19 | Avesthagen Pharma (India) Elpen Pharmaceuticals (Greece) | Avdesp™ (biosimilar for darbepoetin alfa Aranesp®) | anaemia resulting from chronic kidney disorders and cancer chemotherapy | distribution |
Cancer - Oncology - Renal diseases - Kidney diseases | Distribution agreement |
| 2013-11-18 | Novalix (France) Kyowa Hakko Kirin (Japan) | novel drug candidates against protein-protein interaction targets | undisclosed | R&D |
undisclosed | R&D agreement |
